Worldwide prevalence rates for type 2 diabetes mellitus (T2DM) vary considerably. The prevalence of T2DM in Europe is expected to increase 20% within the next 20 years. Effective management of diabetes is a dynamic and individualized process, requiring an appropriate treatment regimen and long-term monitoring. New classes of antihyperglycemic agents are being developed which may help further individualize care with the goal of achieving glycemic control in T2DM.
Tina Vilsbøll, MD, DMSc, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novo Nordisk
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novo Nordisk
Received grants for clinical research from: Merck Sharp & Dohme Corp.; Novo Nordisk
Sebastiano Filetti, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Novo Nordisk
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation; Novo Nordisk
Received grants for clinical research from: Eli Lilly and Company
Johan H. Jendle, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Medtronic, Inc.; Novo Nordisk; Pfizer Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novo Nordisk; Pfizer Inc.
Jack L. Leahy, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Janssen Global Services LLC; Merck & Co., Inc.; Novo Nordisk; sanofi-aventis; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: sanofi-aventis
Received grants for clinical research from: Takeda Pharmaceuticals North America, Inc.
Eduard Montanya, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Intarcia Therapeutics, Inc.; Novo Nordisk
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novo Nordisk
Spouse owns stock, stock options, or bonds from: Almirall Prodesfarma, S.A.
Michael A. Nauck, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amylin Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Berlin-Chemie AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Diartis Pharmaceuticals; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; GlaxoSmithKline; Intarcia Therapeutics, Inc.; MannKind Corporation; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; sanofi-aventis; Takeda Pharmaceuticals North America, Inc.; Versartis, Inc.; Wyeth Pharmaceuticals Inc.
Served as a speaker or a member of a speakers bureau for: Amylin Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Berlin-Chemie AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Diartis Pharmaceuticals; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; GlaxoSmithKline; Intarcia Therapeutics, Inc.; MannKind Corporation; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; sanofi-aventis; Takeda Pharmaceuticals North America, Inc.; Versartis, Inc.; Wyeth Pharmaceuticals Inc.
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Berlin-Chemie AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; GlaxoSmithKline; Merck Sharp & Dohme Corp.; MetaCure Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Roche; Tolerx, Inc.
John R. Petrie, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Novo Nordisk; Roche; sanofi-aventis; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: GlaxoSmithKline; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: JDRF; Merck Serono
Has a research agreement with: Itamar Medical